Related Experiment Videos
Angiogenesis inhibitors in lung cancer
1Department of Thoracic/Head and Neck Medical Oncology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Box 432, Houston 77030, USA. edkim@mdanderson.org
Abstract:
Lung cancer is a major public health problem and the leading cause of cancer-related death worldwide. Its survival rates have changed little over the past 20 years. The best clinical benefit (ie, survival rates) with combination cytotoxic therapies in non-small-cell lung cancer (NSCLC) may have been reached. The need for improved survival rates in NSCLC has driven the development of novel, rationally designed, targeted therapies. Inhibitors of angiogenesis have been developed and are increasingly studied. Potential targets for therapy include inhibitors of vascular endothelial growth factor receptor, endogenous angiogenesis inhibitors, and cyclooxygenase inhibitors. Combining targeted molecules with traditional cytotoxic therapies usually results in lower required chemotherapy doses and fewer, less severe side effects. A number of ongoing randomized studies are underway to evaluate this idea. It is anticipated that these new targeted therapies will play an important role, along with cytotoxic and radiation therapies, in the management of metastatic disease.
Insights
Lung cancer survival rates remain low, prompting research into targeted therapies. Novel treatments, including angiogenesis inhibitors, show promise for improving outcomes in non-small-cell lung cancer.
Area of Science:
- Oncology
- Medical Research
Background:
- Lung cancer is a leading cause of cancer death globally.
- Current survival rates for lung cancer have seen minimal improvement over two decades.
- Standard cytotoxic therapies for non-small-cell lung cancer (NSCLC) may have reached their therapeutic limit.
Purpose of the Study:
- To explore novel, targeted therapies for improving survival rates in non-small-cell lung cancer (NSCLC).
- To investigate the potential of angiogenesis inhibitors as a therapeutic strategy.
- To evaluate the role of targeted therapies in combination with traditional treatments.
Main Methods:
- Review of current therapeutic strategies and limitations in NSCLC.
- Identification of potential molecular targets for novel therapies, including angiogenesis pathways.
- Analysis of preclinical and clinical data on targeted agents.
Main Results:
- Development of targeted therapies, such as vascular endothelial growth factor receptor inhibitors and cyclooxygenase inhibitors, is ongoing.
- Combination of targeted agents with cytotoxic chemotherapy may allow for reduced doses and fewer side effects.
- Randomized studies are evaluating the efficacy of these combined approaches.
Conclusions:
- Targeted therapies represent a promising new avenue for improving NSCLC patient outcomes.
- The integration of targeted agents with conventional therapies is expected to enhance treatment efficacy.
- Future management of metastatic lung cancer will likely involve a multimodal approach including targeted, cytotoxic, and radiation therapies.